Favorable Ad Comm vote for EnteroMedics obesity device

The FDA's Gastroenterology and Urology Devices Panel votes 8:1 in favor of the safety of EnteroMedics' (ETRMMaestro VBLOC Therapy system for the treatment of obesity, but votes 4:5 on the issue of reasonable assurance of efficacy. The final vote, however, was 6:2 recommending approval with one abstention. The FDA usually follows the majority of an Ad Comm vote.

The Maestro is a pacemaker-like device that delivers VBLOC therapy which controls the hunger sensation and sense of fullness by blocking the primary (Vagus) nerve that regulates the digestive system.

Shares are up 15% AH on heavy volume.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs